5 results
To determine non inferiority of two doses of BI 10773 (10 mg/daily and 25 mg/daily) compared to placebo with respect to first occurrence of any of the adjudicated components of the primary composite Major Adverse Cardiovascular Event endpoint (…
To assess whether there is a difference in the outcome in treatment of acute mallet fingers (exist <2 weeks) compared to chronic mallet fingers (exist > 4 weeks), using the same protocol of intensive follow-up by the '…
The primary efficacy variable is the change in PV from baseline as assessed by 3 D ultrasonography after 78 weeks of double-blind treatment with OM 20-40 mg daily compared to ATE 50-100 mg daily.Secondary efficacy variables:Change from baseline PV…
The evaluate which treatment of mallet fingers is better, the conventional mallet therapy via the hospital or the personalized treatment with intensive follow up via the handencentrum. This will be investigated for mallet fingers caused by an…
The aim of this study is to investigate what proportion of HBeAg negative, inactive carriers of the hepatitis B virus with low (< 20,000 IU/mL) load will lose HBsAg when treated with nucleot(s)ide analogue/Peg-IFN combination therapy.